A new low-dose pilocarpine agent can be administered up to twice a day for maximum duration of effect. It is hoped to result in fewer adverse effects than Vuity.
A panel agreed on many aspects of pre-op and intraoperative decision-making. They disagreed, however, when considering issues related to lens selection.